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Large-Vessel Dilatation in Giant Cell Arteritis:
A Different Subset of Disease?
FRANCESCO MURATORE ,1 TANAZ A. KERMANI,2 CYNTHIA S. CROWSON,3
MATTHEW J. KOSTER,3 ERIC L. MATTESON,3 CARLO SALVARANI,1 AND
KENNETH J. WARRINGTON3
Objective. To compare patients with large-vessel giant cell arteritis (LV-GCA) characterized by wall thickening, steno-
sis, and/or occlusion of subclavian arteries to those with subclavian dilatation.
Methods. For the purposes of the present retrospective study, 2 different subsets of LV-GCA were identified and com-
pared from an established cohort of patients with radiographic evidence of subclavian artery vasculitis secondary to
GCA: LV-GCA with wall thickening, stenosis, and/or occlusion of subclavian arteries (Group 1), and LV-GCA with
dilatation of subclavian arteries without wall thickening or stenotic changes (Group 2).
Results. The study included 109 patients in Group 1 and 11 in Group 2. Large-vessel involvement secondary to GCA
was diagnosed significantly later in patients from Group 2 compared to those from Group 1 (median 15.3 versus 0.0
months; P = 0.010). Compared to patients from Group 1, those from Group 2 were more frequently male (17% versus
45%; P = 0.027), ever smokers (42% versus 73%; P = 0.048), and more frequently had a history of coronary artery dis-
ease (11% versus 36%; P = 0.018). At LV-GCA diagnosis, 10 of the 11 patients (91%) from Group 2 had aortic dilatation
compared to 13 of 109 patients (12%) from Group 1 (P < 0.001). During the followup period, the prevalence of aortic
aneurysm was significantly higher in patients from Group 2 compared with those from Group 1 (64% versus 7% at 5
years; P < 0.001).
Conclusion. Two different subsets of LV-GCA were identified. Given the strong association between subclavian artery
dilatation and aortic aneurysm, such patients should be evaluated and monitored carefully for aortic dilatation.
Introduction
Giant cell arteritis (GCA) is the most common systemic
vasculitis in western countries in individuals ages <50
years. It mainly involves large and medium-sized arter-
ies, resulting in a wide spectrum of clinical symptoms
(1). The increased availability of imaging techniques is
making a profound impact in the evaluation and manage-
ment of patients with GCA. Systematic screening of
patients with radiographic imaging has yielded a variable
prevalence of large-vessel involvement, depending on
the technique employed. In prospective imaging studies
of patients with a new diagnosis of GCA, large-vessel dis-
ease (LV-GCA) was seen in 29–83% of patients, and the
subclavian arteries were frequently involved (1). Involve-
ment of the aortic arch branches is generally character-
ized by circumferential wall thickening, long segments of
smooth arterial stenosis, and occlusion (2).
Dilatation of the subclavian/axillary vessels as a mani-
festation of GCA has been only rarely reported in the lit-
erature (2,3). The aim of this study was to compare
patients with subclavian artery stenosis, wall thickening,
or occlusions to the rare subset of patients who had
dilatation of the subclavian arteries.
Patients and methods
This retrospective study included patients from an estab-
lished cohort with radiographic evidence of subclavian
artery vasculitis attributed to LV-GCA, diagnosed at Mayo
Clinic between January 1, 1999 and December 31, 2008 (1).
Methods have been described in detail elsewhere (1).
Briefly, patients with LV-GCA were identified using an
electronic clinical notes search tool (Enterprise Data Trust
portal). Due to the poor performance in patients with
extracranial disease, we did not require that patients fulfill
the American College of Rheumatology 1990 criteria for
classification of GCA (4), with the exception that they
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were required to be ages >50 years. Findings of subclavian
artery involvement attributed to GCA were confirmed by
computed tomography angiography (CTA), magnetic reso-
nance angiography (MRA), or conventional angiography.
Two subsets of LV-GCA were identified and compared.
LV-GCA with wall thickening, stenosis, and/or occlusion
of subclavian arteries comprised Group 1, defined as the
presence of circumferential wall thickening/wall edema
with or without contrast enhancement and/or the presence
of vascular stenosis/occlusion not attributed to atheroscle-
rotic changes on MRA or CTA, or the presence of long seg-
ments of smooth arterial stenosis or smooth tapered
occlusion without adjacent atherosclerotic plaques on
angiography (2). Group 2 contained LV-GCA with dilata-
tion of subclavian arteries without wall thickening or
stenotic changes. Abnormal dilatation of the subclavian
arteries was considered when aneurysm formation was
detected or when the physiologic progressive reduction of
the diameter was not observed (5). Patients with post-
stenotic dilatation of the subclavian arteries were included
in Group 1.
Vascular imaging was performed at Mayo Clinic using a
defined clinical protocol and was evaluated by an expert
vascular radiologist. Patients with a report by the Mayo
Clinic radiologist specifically stating that findings of the
subclavian arteries were consistent with atherosclerosis
(i.e., short, eccentric, focal stenosis, plaque, or calcifica-
tion) or fibromuscular dysplasia (i.e., the classic string-of-
beads appearance on angiography) were excluded. In the
presence of subclavian focal concentric narrowing without
arterial wall thickening, edema, or contrast uptake on
cross-sectional vascular imaging, a diagnosis of fibromus-
cular dysplasia could not be excluded. In the absence of
signs or symptoms of GCA, elevation of inflammatory
markers, evidence of aortic involvement at imaging stud-
ies, or histologic confirmation of vasculitis, these patients
were excluded. Patients with a diagnosis of Behcet’s dis-
ease, Takayasu arteritis, sarcoidosis, or other connective
tissue disease were excluded as well.
The available medical records of study participants
were reviewed from the date of GCA diagnosis to the end
of the study followup (December 31, 2010), the last visit
at Mayo Clinic, or death. Only patients who were fol-
lowed at Mayo Clinic for at least 6 months after GCA
diagnosis were considered for the outcomes analysis.
Relapse was defined as the reappearance of symptoms of
GCA and/or polymyalgia rheumatica associated with a
rise in erythrocyte sedimentation rate and/or C-reactive
protein level. Isolated increases in inflammatory markers
in the absence of other causes were considered relapses
only if the treating rheumatologist increased the gluco-
corticoid/immunosuppressive therapy with subsequent
improvement. The study was approved by the Institu-
tional Review Board at Mayo Clinic.
Statistical analysis. Continuous data were described as
mean  SD or median and 25th/75th percentiles, and
categorical variables as percentage. Wilcoxon’s rank sum
test was used to analyze continuous variables, and chi-
square tests were used for categorical variables. Kaplan-
Meier methods and log rank tests were used to estimate
the rate of development of outcomes during followup,
which is especially necessary because the length of
followup differs between the 2 study cohorts. The relapse
rate was calculated using person-year methods, and
differences in relapse rates between the groups were
computed assuming the relapse rates follow a Poisson
distribution. Analyses were performed using SAS soft-
ware, version 9.4.
Results
From the original cohort of 120 patients with LV-GCA,
109 cases (91%) of LV-GCA with wall thickening, steno-
sis, and/or occlusion (Group 1) and 11 cases (9%) of LV-
GCA with dilatation of subclavian arteries (Group 2)
were identified. All 120 patients had imaging of the tho-
racic aorta and its major branches; 71 patients also had
imaging of the abdominal aorta and its major branches.
Baseline demographic and clinical characteristics for the
2 study groups are reported in Table 1.
Temporal artery biopsy (TAB) was performed in 73 of
the 109 patients from Group 1 (67%) and in 6 of the 11
patients from Group 2 (55%) and was positive for GCA in
36 of 73 (49%) and 5 of 6 (83%), respectively (P = 0.11). At
LV-GCA diagnosis, thoracic aorta involvement was
observed in 56 patients (52%) from Group 1 and in 10
patients (91%) from Group 2 (P = 0.013). The type of aortic
involvement in the 2 subsets of LV-GCA was significantly
different; 10 of 11 patients (91%) in Group 2 had aortic
dilatation (aneurysm or ectasia) compared to 13 of 109
(12%) in Group 1 (P < 0.001). Aortic aneurysm was also
statistically different and noted in 8 of 11 patients (73%)
in Group 2 compared to 6 of 109 patients (6%) in Group 1
(P < 0.001). Conversely, only 2 of 11 patients (18%) from
Group 2 had aortic wall thickening compared to 48 of 109
patients (44%) from Group 1 (P = 0.097).
A total of 91 patients (84%) from Group 1 and 11
patients (100%) from Group 2 had a followup period
longer than 6 months and were included in the outcomes
analysis. Treatment and outcome variables for the 2
Significance & Innovations
• Two different subsets of large-vessel giant cell
arteritis were identified: the first, more common,
was characterized by wall thickening, stenosis,
and/or occlusion of subclavian arteries, and the
second, less common, was characterized by di-
latation of subclavian arteries.
• Patients with subclavian artery dilatation have
more aortic dilatation and less aortic wall thick-
ening at diagnosis.
• Given the strong association between subclavian
artery dilatation and aortic aneurysm, such patients
should be evaluated and monitored carefully for
aortic dilatation.
LV Dilatation in GCA 1407
study groups are reported in Table 2. During the fol-
lowup period, the relapse rate was higher in patients
from Group 1 compared to those from Group 2, and a
greater proportion of patients in Group 1 were treated
with additional immunosuppressive agents. There was
no difference in the cumulative glucocorticoid dose at 1
year, nor in the median time to discontinue glucocorti-
coid therapy between the 2 groups. The prognosis of LV-
GCA was excellent in both study groups. No patients
developed major upper-extremity ischemic complications
or subclavian dissection/rupture during followup.
The prevalence of aortic aneurysm during followup was
significantly higher in patients from Group 2 compared
with those from Group 1 (Table 2). None of the 109
patients from Group 1 developed subclavian dilatation
during the followup period. Ten patients from Group 2
(91%) and 2 patients from Group 1 (2%) underwent
surgical aortic aneurysm repair. Active giant cell aortitis
was found in 10 of 12 patients (83%; 8 from group 2, and 2
from group 1); severe cystic medial degeneration was
found in the remaining 2 patients, in 1 with evidence of
laminar necrosis. At the time of aortic surgery, none of the
12 patients were using glucocorticoid therapy. Six of the
12 patients (50%) had no symptoms and/or sign of active
GCA and had normal inflammatory markers; 3 of the 12
patients (25%) had isolated elevation of inflammatory
markers without symptoms and/or sign of active GCA. The
remaining 3 patients (25%) had systemic symptoms (in 1
with associated polymyalgic symptoms) and elevation of
inflammatory markers. There were no significant differ-
ences in the prevalence of the other outcomes evaluated
during followup (angina or myocardial infarction, tran-
sient ischemic attack or stroke, and lower limb arterial dis-
ease; data not shown).
Table 1. Baseline demographics, clinical manifestations, and laboratory findings of LV-GCA patients with wall thickening,






(n = 11) P
Age at GCA diagnosis, mean  SD years 68.0  7.6 70.5  6.5 0.26
Women 90/109 (83)† 6/11 (55)† 0.027†
Time from symptom onset to diagnosis, median (Q1, Q3) months 3.5 (1.8, 7.2) 3.2 (2.4, 4.0) 0.78
Time from GCA to LVI diagnosis, median (Q1, Q3) months 0.0 (0.2, 0.8)† 15.3 (0.0, 64.9)† 0.010†
History of PMR prior to GCA diagnosis 30/109 (28) 1/11 (9) 0.18
Prednisone use prior to GCA diagnosis 19/109 (17) 1/11 (9) 0.48
Hypertension 50/106 (47) 6/10 (60) 0.44
Hyperlipidemia 42/108 (39) 5/11 (45) 0.67
Ever smoker 45/108 (42)† 8/11 (73)† 0.048†
Current smoker 10/108 (9) 0/11 (0) 0.29
Diabetes mellitus 4/109 (4) 0/11 (0) 0.52
Coronary artery disease 12/109 (11)† 4//11(36)† 0.018†
Symptoms
Any cranial symptoms 46/109 (42) 3/11 (27) 0.34
Permanent vision changes 4/109 (4) 1/11 (9) 0.39
Any vision changes 13/109 (12) 2/11 (18) 0.55
Constitutional symptoms 59/109 (54) 5/11 (45) 0.58
PMR symptoms 24/109 (22) 1/11 (9) 0.31
Upper-extremity claudication 62/109 (57)† 1/11 (9)† 0.002†
Physical examination findings
Temporal artery abnormalities 12/79 (15) 1/10 (10) 0.66
Vascular bruits 42/102 (41)† 0/10 (0)† 0.010†
Abnormal radial pulse 66/103 (64)† 0/10 (0)† < 0.001†
Upper-extremity blood pressure discrepancy 60/103 (58)† 0/10 (0)† < 0.001†
Aortic regurgitation murmur 4/103 (4)† 4/10 (40)† < 0.001†
Laboratory
ESR, mean  SD mm/hour 67.3  35.9 61.4  51.2 0.57
CRP, mean  SD mg/liter 64.4  64.5 62.8  66.0 0.84
Hemoglobin, mean  SD grams/dl 13.0  11.9 12.4  2.0 0.43
White blood count, mean  SD 910³/ll 8.5  2.3 7.8  2.7 0.11
Platelets, mean  SD 910³/ll 407.5  132.9† 308.4  156.9† 0.033†
Temporal artery biopsy positive 36/73 (49) 5/6 (83) 0.11
American College of Rheumatology criteria 42/109 (39) 5/11 (45) 0.65
Prednisone started at GCA diagnosis
Prednisone dose, mean  SD mg 54.3  14.1 51.1  17.6 0.54
* Values are the number of patients who were positive/number of patients for whom data were available (%) unless indicated otherwise. LV-GCA
= large-vessel giant cell arteritis; Q1, Q3 = quintile 1, quintile 3; LVI = large-vessel involvement; PMR = polymyalgia rheumatica; ESR = erythrocyte
sedimentation rate; CRP = C-reactive protein.
† Statistically significant.
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Discussion
The present study is a novel analysis aimed at comparing
2 different subsets of LV-GCA patients involving the sub-
clavian arteries according to lesion type: wall thickening,
stenosis, and/or occlusion versus dilatation. Patients with
subclavian artery dilatation are more frequently male and
smokers (ever), more frequently have a history of coronary
artery disease, and have fewer clinical features of vascular
insufficiency. Aortic dilatation was more frequent at diag-
nosis, and a higher prevalence of aortic aneurysm was
observed in these patients during followup.
Dilatation of the aortic arch branches as a manifestation
of GCA has been rarely reported. In the present study, we
found subclavian artery dilatation in 11 of 120 patients
(9%) with LV-GCA, all with histologic confirmation of
GCA (6 with evidence of giant cell aortitis, 3 with TAB
positive for GCA, and 2 with both giant cell aortitis and
TAB positive for GCA). In a retrospective study of 65
patients with LV-GCA diagnosed by conventional angiog-
raphy, Stanson (2) reported 3 patients (5%) with dilated
arterial segments, almost aneurysmal in size, a frequency
slightly lower than that seen in the present study. Simi-
larly, aneurysm of the subclavian arteries was reported by
conventional angiography in 1 of 32 GCA patients (3%)
enrolled in a longitudinal multicenter observational
cohort of patients with established LV-GCA (3). To date,
only 1 study has prospectively evaluated the prevalence,
characteristics, and topography of large-vessel involve-
ment using CTA in 40 newly diagnosed, biopsy-proven,
untreated GCA patients. In this study, dilatation of the aor-
tic branches was not seen, while thickening was found in
23 of 40 patients with newly diagnosed GCA (57.5%) (5).
Differences in the study design may explain the discrepant
results observed (prospective study of unselected, newly
diagnosed, consecutive, biopsy-proven GCA patients ver-
sus retrospective studies of cohorts of patients with estab-
lished radiographic evidence LV-GCA).
In the current study, large-vessel involvement secondary
to GCA was diagnosed significantly later in patients from
Group 2 compared to those from Group 1, likely due to the
absence of signs and/or symptoms of upper-extremity vas-
cular insufficiency in patients with subclavian dilatation.
Subclavian dilatation is likely a late complication of vas-
cular inflammation, and delayed diagnosis may have con-
tributed to these findings. In this regard, only 1 study
prospectively evaluated the outcome of CTA findings of
large-vessel inflammation (wall thickening) in 35 newly
diagnosed biopsy-proven GCA patients after a median of
13.5 months of glucocorticoid therapy (6). Wall thickening
of the aortic branches was still present in 12 of the 19
patients (63%) who had this finding at diagnosis, while
development of aortic branch dilatation was not reported.
Patients with subclavian dilatation had similar exposure
to glucocorticoids prior to GCA diagnosis and during the
treatment course, compared to those with stenotic lesions,
and therefore, differences in treatment are unlikely to
explain the study findings. None of the 11 patients from
Group 2 had subclavian artery thickening, and none of the
109 patients from Group 1 developed subclavian dilata-
tion during the followup period. These data suggest that 2
distinct subsets of LV-GCA may be present.
One of the most intriguing findings is that aortic
involvement differed significantly between the 2 subsets
of LV-GCA. Compared to those with subclavian thick-
ening, patients with subclavian artery dilatation had sig-
nificantly more aortic dilatation and less aortic wall
thickening at LV-GCA diagnosis. Furthermore, the preva-
lence of aortic aneurysm during the followup period was
significantly higher in patients with subclavian dilatation.
Table 2. Comparison of treatment and outcome variables in LV-GCA patients with wall thickening,
stenosis, and/or occlusion of subclavian arteries (Group 1) and those with LV-GCA with dilatation of





(n = 11) P†
Duration of followup, median (IQR) years 3.3 (2.1–6.4)‡ 5.5 (4.5–6.6)‡ 0.031‡
Relapses, no. 198 17 –
Relapse rate per 10 person-years 5.2 (4.5–6.0)‡ 2.7 (1.6–4.3)‡ < 0.001‡
Cumulative corticosteroid dose at 1 year, mean  SD gm 11.6  5.5 10.0  8.9 0.39
Additional immunosuppressive therapy, no.§ 50 3 –
Within 1 year of GCA diagnosis 40 (28–49)‡ 20 (0–41)‡ 0.049‡
Within 2 years 49 (37–58)‡ 20 (0–41)‡ –
Within 5 years 61 (47–72)‡ 20 (0–41)‡ –
Rate of aortic aneurysm development, no.§ 5 9 –
Within 1 year after GCA diagnosis 2 (0–5)‡ 54 (13–76)‡ < 0.001‡
Within 2 years 4 (0–8)‡ 54 (13–76)‡ –
Within 5 years 7 (1–12)‡ 64 (20–83)‡ –
* Values are the rate (95% confidence interval) unless indicated otherwise. LV-GCA = large-vessel giant cell arteritis; IQR =
interquartile range (25th and 75th percentiles).
† Differences between groups were tested using rank sum tests for duration of followup and cumulative corticosteroid dose,
Poisson methods for relapse rate, and log rank test for all others. For medications used by only 1 or 0 patients in a group,
log rank P values were not available.
‡ Statistically significant.
§ Rates determined using Kaplan-Meier estimate.
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Patients with GCA have a 6.6–17.3-fold increased risk of
developing thoracic aortic aneurysm compared with the
general population (7,8). Aortic aneurysm is a delayed
complication of GCA (22.2% and 33.3% of patients with
GCA after a median disease duration of 5.4 and 10.3 years,
respectively) (9). Patients with GCA who develop aortic
aneurysm are at high risk of aortic dissection and rupture
and have an increased mortality compared with the gen-
eral population (10,11). The incidence of aortic aneurysm/
dissection increases 5 years after GCA diagnosis and con-
tinues to increase thereafter (11). Consistent predictors of
aortic aneurysm/dissection in GCA are lacking (10,12).
Furthermore, there is no association between aneurysm
size and rate of growth and risk of dissection/rupture in
patients with GCA (13). A long-term screening program for
aortic aneurysm by imaging modalities is therefore manda-
tory in all GCA patients (10).
More recently, prospective studies have evaluated the
prevalence of aortic involvement in unselected, newly
diagnosed patients with GCA (5,14). Aortic wall thicken-
ing was seen in 45–65% and aortic dilatation in 15–23%
of GCA patients. Only rarely were aortic wall thickening
and aortic dilatation found in the same patients or in the
same segment of the aorta (5,14,15).
Taken together, these findings suggest that large-vessel
thickening is a common and early manifestation of GCA,
while large-vessel dilatation is a less frequent manifesta-
tion that could occur both in the early and late course of
the disease. Mechanisms underlying the response of the
artery to injury are not fully understood, and different
pathophysiologic mechanisms may account for the vari-
able response to large-vessel inflammation. Immunologic
responses appears to regulate the extent of intimal hyper-
plasia, resulting in wall thickening and luminal stenosis
(16). In some patients, however, vascular injury may lead
to arterial dilatation in the absence of intimal thickening.
Large-vessel dilatation could reasonably be a consequence
of previous or persistent vessel-wall inflammation (active
aortitis was found in 83% of our patients who underwent
aortic surgery), but a direct link between inflammation
and subsequent dilatation has never been established.
In the present study, patients with subclavian artery
dilatation were more frequently male, were ever smokers,
and more frequently had a history of coronary artery dis-
ease. These cardiovascular risk factors have been previ-
ously associated with aortic dilatation in GCA (10,12).
One hypothesis is that patients with cardiovascular risk
factors may have early damage of the elastic fibers and
muscular layer, or inefficient vascular repair or remodel-
ing after injury that contribute to progressive arterial
dilatation (6). Sex-associated factors may also play a sig-
nificant role (5).
The major limitation of our study is its retrospective
design, which relies on documentation in the medical
records. The treatment of patients and the addition of
adjunctive immunosuppressive therapy was not stan-
dardized, but was at the discretion of the treating physi-
cian. Finally, the number of patients with subclavian
artery dilation identified was small, and the exact delin-
eation of the differences in these 2 subsets of LV-GCA
may require larger multicenter cohorts. However, the
present study is to our knowledge the first of its nature
and has a number of strengths, including the large cohort
size and long duration of followup.
In conclusion, our findings indicate that there may be
2 different subsets of LV-GCA involving the subclavian
arteries, one characterized by occlusive disease, and the
second characterized by arterial dilatation. Patients with
subclavian artery dilatation had more aortic dilatation at
diagnosis and a higher prevalence of aortic aneurysm
during followup. In view of this observation, such
patients should be evaluated and monitored carefully for
aortic complications.
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